Article
Tumor mutational burden shapes success and resistance in cancer immunotherapy
2025-08-12
Abstract excerpt
Immunotherapy, particularly immune checkpoint blockade, has transformed cancer treatment, yet durable responses remain limited to a subset of patients and cancer types. Many tumors exhibit innate resistance or acquire resistance through immune evasion or neoantigen editing. A central factor in shaping these outcomes is the tumor mutational burden. However, cancer mutations can enhance or impair both cellular repli...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 1cdb77e6-9927-5b31-b098-565a2ca93439
- DOI
- 10.1101/2025.08.09.669487
